Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

ClinicalTrials.gov ID: NCT06744647

Public ClinicalTrials.gov record NCT06744647. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients With Antibody-Mediated Rejection After Kidney Transplantation

Study identification

NCT ID: NCT06744647
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Enrollment: 45 participants

Conditions and interventions

Conditions

Interventions

ALXN2030 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 6, 2025
Primary completion: Oct 10, 2027
Completion: Nov 6, 2028
Last update posted: Apr 26, 2026

2025 – 2028

United States locations

U.S. sites: 23
U.S. states: 17
U.S. cities: 20

Facility	City	State	ZIP	Site status
Research Site	Birmingham	Alabama	35249	Recruiting
Research Site	Scottsdale	Arizona	85259	Recruiting
Research Site	Los Angeles	California	90095	Recruiting
Research Site	Orange	California	92868	Recruiting
Research Site	Tampa	Florida	33606	Recruiting
Research Site	Atlanta	Georgia	30309	Recruiting
Research Site	Kansas City	Kansas	66160	Recruiting
Research Site	Ann Arbor	Michigan	48109	Recruiting
Research Site	Detroit	Michigan	48202	Recruiting
Research Site	Livingston	New Jersey	07039	Recruiting
Research Site	New York	New York	10016	Withdrawn
Research Site	New York	New York	10021	Recruiting
Research Site	New York	New York	10029	Recruiting
Research Site	New York	New York	10032	Recruiting
Research Site	Durham	North Carolina	27705	Recruiting
Research Site	Cincinnati	Ohio	45267	Not yet recruiting
Research Site	Philadelphia	Pennsylvania	19140	Not yet recruiting
Research Site	Charleston	South Carolina	29425	Withdrawn
Research Site	Dallas	Texas	75235	Recruiting
Research Site	Houston	Texas	77030	Recruiting
Research Site	Richmond	Virginia	23298	Recruiting
Research Site	Seattle	Washington	98195	Recruiting
Research Site	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06744647, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 26, 2026 · Synced Apr 29, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06744647 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →